((自动化翻译由路透提供，请见免责声明 ))
路透10月17日 - ** 医疗设备制造商Delcath Systems Inc 股价上涨5.8%，报10.06美元。
** 根据LSEG汇编的数据，该公司预计 (link)，第三季度营收为1120万美元，高于分析师平均预期的945万美元。
** 该公司称其第三季度在美国的收入为1000万美元，来自于Hepzato Kit的商业化，这是一种治疗癌症的药物和设备组合产品。
** DCTH表示， 1,000万美元的美国季度收入里程碑触发了2,500万美元的融资，该公司将利用这笔资金支持正在进行的商业化启动，并投资于新的试验，以扩大其计划于2025年启动的适应症。
** 公司将于11月8日公布季度财务报告
** 截至上次收盘，股价累计上涨约 140.98
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.